Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis ...Middle East

GUANGZHOU, China, Feb. 1, 2024 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing has begun in Phase IA/IIB clinical trial to study efficacy and safety of...

Hence then, the article about bio thera solutions announces initiation of phase ib iia clinical trial for bat6026 a monoclonal antibody targeting ox40 in patients with moderate to severe atopic dermatitis was published today ( Thursday 01/02/2024 - 01:44 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis )

Also on site :

• Ukraine will try “to get some concessions” from Trump at meeting
• Numbrix 9 - December 28
• Getting hired in 2026 is all about your ‘microcredentials’ says CEO of $1.3 billion learning platform—this is what he tells Gen Z to focus on